PALISADE BIO, INC. — fact timeline

PALISADE BIO, INC.: Increased authorized shares of common stock from 300,000,000 to 450,000,000 via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2026-06-11).

“On June 11, 2026, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to increase the number of authorized shares of common stock from 300,000,000 shares to 450,000,000 shares.”

PALISADE BIO, INC. shareholders approved Approval of equity award grants to our non-employee directors at the 2026-06-10 meeting.

“The Company’s stockholders approved equity grants to the Company’s non-employee directors.”

PALISADE BIO, INC. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-10 meeting.

“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement.”

PALISADE BIO, INC. shareholders approved Approval of the Amended and Restated Palisade Bio, Inc. 2021 Employee Stock Purchase Plan at the 2026-06-10 meeting.

“The Company’s stockholders approved the Amended and Restated Palisade Bio, Inc. 2021 Employee Stock Purchase Plan.”

PALISADE BIO, INC. shareholders approved Approval of the Amended and Restated Palisade Bio, Inc. 2021 Equity Incentive Plan at the 2026-06-10 meeting.

“The Company’s stockholders approved the Amended and Restated Palisade Bio, Inc. 2021 Equity Incentive Plan.”

PALISADE BIO, INC. shareholders approved Approval of an Amendment to the Amended and Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock at the 2026-06-10 meeting.

“The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000 (which will result in an increase in the total number of authorized shares of capital stock of the Company from 307,000,000 to 457,000,000).”

PALISADE BIO, INC. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-06-10 meeting.

“The Company’s stockholders ratified the selection of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

PALISADE BIO, INC. shareholders approved Election of Directors at the 2026-06-10 meeting.

“The Company’s stockholders elected the four (4) persons listed below as directors, each to serve until the Company’s 2027 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.”

Jordan Zwick was appointed as Director at PALISADE BIO, INC..

“On June 10, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of Palisade Bio, Inc. (the “Company”) expanded the size of the Board from five to six directors and appointed Jordan Zwick to the Board.”

PALISADE BIO, INC. reported financial results for the first quarter ended March 31, 2026.

“On May 12, 2026, Palisade Bio, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026.”

PALISADE BIO, INC.: Increased authorized shares of common stock from 280,000,000 to 300,000,000 (effective 2025-12-03).

“On December 3, 2025, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the "Amendment") with the Secretary of State of the State of Delaware to increase the number of authorized shares of common stock from 280,000,000 shares to 300,000,000 shares.”

PALISADE BIO, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“April 30, 2025, Palisade Bio, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that for 30 consecutive trading days preceding the date of the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice has no effect on the listing of the Company’s common stock at this time, and the Company’s common stock continues to trade on The Nasdaq Cap”

Margery Fischbein was appointed as Director at PALISADE BIO, INC..

“On May 7, 2024 (the “Effective Date”), the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) appointed Margery Fischbein to the Board.”

PALISADE BIO, INC. entered into Purchase Agreement with an institutional investor valued at approximately $4.0 million (effective 2024-05-01).

“On May 1, 2024, Palisade Bio, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor (the “Purchaser”), pursuant to which the Company agreed to sell and issue, in a private placement, (i) 85,100 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”) and (ii) 530,142 prefunded warrants (the “Prefunded Warrants”) at a purchase price per Share or Prefunded Warrant of $6.5015 (less the applicable exercise price of each Prefunded Warrant purchased) (the “Offering”).”

PALISADE BIO, INC.: Filed amendment to certificate of incorporation to effect a 1-for-15 reverse stock split, effective April 5, 2024 (effective 2024-04-05).

“On April 2, 2024, the Company filed an amendment to its amended and restated certificate of incorporation, as amended (the "Amendment") with the Secretary of State of Delaware with such Amendment becoming effective at 5:00 p.m. Eastern Time on Friday, April 5, 2024.”

PALISADE BIO, INC. reported financial results for the year ended December 31, 2023.

“Palisade Bio, Inc. (the "Company") reported its financial results for the year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.01 and is incorporated herein by reference.”

PALISADE BIO, INC. shareholders approved The approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect, at the discretion of the Company’s Board of Directors: a reverse split of the Company’s common stock, at a ratio not less than 1-for-2 and not greater than 1-for-15, with the exact ratio to be at the 2024-03-25 meeting.

“On March 25, 2024, the Company held a virtual special meeting of its shareholders (“Special Meeting”) at 10:00 a.m. Pacific Time. Shareholders of record as of the close of business on February 2, 2024 (“Record Date”) were entitled to vote. As of the Record Date, 12,129,907 shares of the Company’s common stock were issued, outstanding, and entitled to vote, of which 6,583,805 shares of common stock, constituting a quorum, were represented at the meeting, in person or by proxy. The final results of the shareholder vote on the proposal brought before the Special Meeting was as follows: Proposal 1 . The approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect, at the discretion of the Company’s Board of Directors: a reverse split of the Company’s common stock, at a ratio not less than 1-for-2 and not greater than 1-for-15, with the exact ratio to be set within that range at the discretion of the Board of Directors, without further approval or au”

PALISADE BIO, INC. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(b)(1)(A), 5605(c)(4)).

“March 22, 2024, the Company received a notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with the audit committee requirements set forth in Nasdaq Listing Rule 5605. More specifically, as of the date of the Notice, the audit committee consists of only two (2) members, both of which are “independent directors,” as that term is defined in Nasdaq Listing Rule 5605(a)(2). Per Nasdaq Rules, the audit committee is required to be comprised of three (3) independent directors. The Notice states that”

PALISADE BIO, INC.: Amended and restated bylaws to remove classified board structure and provide for annual election of all directors, effective at 2024 annual meeting (effective 2024-02-29).

“On February 29, 2024, the Board adopted amended and restated bylaws (the “Amended and Restated Bylaws”) for the purpose of removing the Company’s classified Board structure and to provide for the annual election of all members of the Board.”

Mary Ann Gray resigned as Director at PALISADE BIO, INC..

“On March 4, 2024, Mary Ann Gray, Ph.D. informed the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) that she is resigning as a member of the Board effective immediately.”

Robert Trenschel resigned as Director at PALISADE BIO, INC..

“James Neal, Stephanie Diaz, Dr. Cristina Csimma, and Dr. Robert Trenschel (collectively, the “Resigning Directors”), informed the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) that each is resigning as a member of the Board effective immediately.”

Cristina Csimma resigned as Director at PALISADE BIO, INC..

“James Neal, Stephanie Diaz, Dr. Cristina Csimma, and Dr. Robert Trenschel (collectively, the “Resigning Directors”), informed the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) that each is resigning as a member of the Board effective immediately.”

Stephanie Diaz resigned as Director at PALISADE BIO, INC..

“James Neal, Stephanie Diaz, Dr. Cristina Csimma, and Dr. Robert Trenschel (collectively, the “Resigning Directors”), informed the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) that each is resigning as a member of the Board effective immediately.”

James Neal resigned as Director at PALISADE BIO, INC..

“James Neal, Stephanie Diaz, Dr. Cristina Csimma, and Dr. Robert Trenschel (collectively, the “Resigning Directors”), informed the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) that each is resigning as a member of the Board effective immediately.”

PALISADE BIO, INC. entered into warrant inducement agreements with certain accredited and institutional holders valued at approximately $2,502,717 (effective 2024-01-30).

“On January 30, 2024, Palisade Bio, Inc. (the “Company”) entered into warrant inducement agreements (the “Agreements”) with certain accredited and institutional holders (collectively, the “Holders”)”

PALISADE BIO, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“October 19, 2023, Palisade Bio, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that for 30 consecutive trading days preceding the date of the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice has no effect on the listing of the Company’s common stock at this time, and the Company’s common stock continues to trade on The Nasdaq C”

PALISADE BIO, INC. entered into Placement Agent Warrants with Ladenburg Thalmann & Co. Inc. valued at 140,364 warrants, term of five years, exercise price of $1.05 per share (effective 2023-09-07).

“The Placement Agent Warrants have a term of five (5) years from the commencement of sales, an exercise price of $1.05 per share, and are not being registered pursuant to this Offering.”

PALISADE BIO, INC. entered into Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. valued at cash fee equal to 7.75% of gross proceeds, payment of up to $95,000 for certain expenses, and warran (effective 2023-09-07).

“In connection with the Offering, we entered into a placement agency agreement (“Placement Agency Agreement”) with Ladenburg Thalmann & Co. Inc. (“Placement Agent”) whereby the Placement Agent receives (i) an aggregate cash fee equal to 7.75% of the gross proceeds received by the Company from the sale of the Shares, (ii) payment of up to $95,000 for certain expenses incurred in the Offering, and (iii) warrants to purchase up to 6.0% of the aggregate Shares sold in the Offering, or an aggregate of 140,364 placement agent warrants (the “Placement Agent Warrants”).”

PALISADE BIO, INC. entered into Securities Purchase Agreement with certain institutional investors valued at 2,339,398 shares at $0.84 per share for aggregate gross proceeds of approximately $1.97 million (effective 2023-09-07).

“Entry into a Material Definitive Agreement. Registered Direct Offering of Shares On September 7, 2023, Palisade Bio, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue an aggregate of 2,339,398 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a purchase price per share of $0.84 (the “Offering”).”

Mitchell Jones was appointed as Chief Medical Officer at PALISADE BIO, INC..

“Mitchell Jones, M.D., Ph.D. (“Dr. Jones”) has been appointed Chief Medical Officer effective September 5, 2023”

PALISADE BIO, INC. entered into Research Collaboration and License Agreement with Giiant Pharma Inc. valued at The Company is receiving an exclusive worldwide license to develop, manufacture, and commercialize s (effective 2023-09-01).

“On September 1, 2023 (the “Effective Date”), Palisade Bio, Inc. (the “Company”) entered into a Research Collaboration and License Agreement (the “License Agreement”) with Giiant Pharma Inc. (“Giiant”) whereby the Company is receiving an exclusive (even as the Giiant and its affiliates), worldwide license (with the right to sublicense in multiple tiers) to develop, manufacture, and commercialize substantially all of the assets of Giiant, including: (i) the GT-2018 compound and (ii) the GT-1908 compound and the associated intellectual property around each of the foregoing.”

PALISADE BIO, INC. shareholders approved Approval, on a non-binding, advisory basis, the frequency of holding future advisory votes on executive compensation every 1, 2, or 3 years. at the 2023-06-08 meeting.

“Proposal 6. Approval, on a non-binding, advisory basis, the frequency of holding future advisory votes on executive compensation every 1, 2, or 3 years. The Company’s stockholders approved, on an advisory basis, one (1) year as the frequency of holding future advisory votes on executive compensation. The Final results were as follows: 1 Year 2 Years 3 Years Withhold / Abstentions Broker Non-Votes 665,444 46,080 589,820 30,764 1,618,807”

PALISADE BIO, INC. shareholders approved Approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers. at the 2023-06-08 meeting.

“Proposal 5. Approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The final voting results were as follows: Votes Non-Votes 765,257 553,499 13,352 1,618,807”

PALISADE BIO, INC. shareholders approved Approval of amendments to the Palisade 2021 Employee Stock Purchase Plan to increase (i) the number of shares of common stock authorized under the plan by 109,944 shares and (ii) the annual evergreen share increase amount from 1% to 2.5% of the outstanding shares of common stock on January 1 of each at the 2023-06-08 meeting.

“Proposal 4. Approval of amendments to the Palisade 2021 Employee Stock Purchase Plan to increase (i) the number of shares of common stock authorized under the plan by 109,944 shares and (ii) the annual evergreen share increase amount from 1% to 2.5% of the outstanding shares of common stock on January 1 of each year. year. The Company’ stockholders approved the amendments to the 2021 Employee Stock Purchase Plan. The final voting results were as follows: Votes Non-Votes 763,625 552,036 16,447 1,618,807”

PALISADE BIO, INC. shareholders approved Approval of amendments to the Palisade 2021 Equity Incentive Plan to increase (i) the number of shares of common stock issuable under the plan by 708,072 shares and (ii) the annual evergreen share increase amount from 4% to 7.5% of the outstanding shares of common stock on January 1 of each year; an at the 2023-06-08 meeting.

“Proposal 3. Approval of amendments to the Palisade 2021 Equity Incentive Plan to increase (i) the number of shares of common stock issuable under the plan by 708,072 shares and (ii) the annual evergreen share increase amount from 4% to 7.5% of the outstanding shares of common stock on January 1 of each year; and the approval of conditional grants to employees which are exercisable or convertible for up to an aggregate of 209,700 shares of common stock. The Company’ stockholders approved the amendments to the 2021 Equity Incentive Plan. The final voting results were as follows: Votes Non-Votes 714,204 611,973 5,931 1,618,807”

PALISADE BIO, INC. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the selection of Baker Tilly US, LLP by the Audit Committee of the Board as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-08 meeting.

“Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the selection of Baker Tilly US, LLP by the Audit Committee of the Board as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results were as follows: Votes Non-Votes 2,732,124 198,268 20,523 0”

PALISADE BIO, INC. shareholders approved Election of Directors. The Company’s stockholders elected the three (3) persons listed below as Class III directors, each to serve until the Company’s 2026 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. at the 2023-06-08 meeting.

“Proposal 1. Election of Directors. The Company’s stockholders elected the three (3) persons listed below as Class III directors, each to serve until the Company’s 2026 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. The final voting results were as follows: Name Votes Withheld Broker Non-Votes James Neal 833,667 498,441 1,618,807 J.D. Finley 837,917 494,191 1,618,807 Mary Ann Gray, Ph.D. 495,347 495,347 1,618,807”

PALISADE BIO, INC. entered into Purchase Agreements with certain institutional and accredited investors valued at aggregate gross proceeds to the Company of approximately $6.0 million (effective 2023-04-03).

“On April 3, 2023, Palisade Bio, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional and accredited investors (the “Purchasers”)”

J.D. Finley was appointed as Director at PALISADE BIO, INC..

“On February 2, 2023, the Board appointed J.D. Finley to the Board.”

Robert McRae was appointed as Chief Operating Officer at PALISADE BIO, INC..

“On February 2, 2023, the Company appointed Robert McRae as the Company’s Chief Operating Officer.”

PALISADE BIO, INC. entered into Purchase Agreements with certain institutional and accredited investors valued at approximately $2.5 million (effective 2022-12-30).

“On December 30, 2022, Palisade Bio, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional and accredited investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of (i) 476,842 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a purchase price per share of $2.375, and (ii) registered prefunded warrants (the “Registered Prefunded Warrants”) to purchase up to 37,000 shares of Common Stock at a purchase price of $2.3749 per Registered Prefunded Warrant (the “Registered Offering”).”

Herbert B. Slade was appointed as chief medical officer at PALISADE BIO, INC..

“On November 17, 2022, the Board of Directors of Palisade Bio, Inc. (“Company”) appointed Herbert B. Slade, MD FAAAAI, to serve as the Company’s chief medical officer.”

PALISADE BIO, INC.: Amendment to certificate of incorporation to effect a 1-for-50 reverse stock split and reduce authorized shares of common stock from 300,000,000 to 280,000,000 (effective 2022-11-15).

“On November 14, 2022, the Company filed an amendment to its amended and restated certificate of incorporation (“Amendment”) with the Secretary of State of Delaware with such Amendment becoming effective at 5:00 p.m. Eastern Time on Tuesday November 15, 2022. The purpose of the Amendment is to (i) effect the Reverse Stock Split and (ii) complete the Authorized Share Reduction.”

Michael Dawson was terminated as Chief Medical Officer at PALISADE BIO, INC..

“the employment of Michael Dawson, MD, was terminated by Palisade Bio, Inc.”

J.D. Finley was appointed as Chief Executive Officer (principal executive officer), interim; continuing as Chief Financial Officer at PALISADE BIO, INC..

“As of the Effective Date, J.D. Finley, the Company’s current Chief Financial Officer, was appointed by the Board to serve as the Company’s Chief Executive Officer (principal executive officer), on an interim basis.”

Thomas Hallam resigned as Chief Executive Officer and member of the Board of Directors at PALISADE BIO, INC..

“Effective October 11, 2022 (the “Effective Date”), Thomas Hallam, Ph.D., the Chief Executive Officer and a member of the Board of Directors (the “Board”) of Palisade Bio, Inc. and its wholly owned subsidiary, Leading Biosciences, Inc. (collectively the “Company”) resigned as both Chief Executive Officer and as a member of the Board, of both entities, to pursue other opportunities.”